Patients who achieved HIV virologic suppression tended to be older and were more likely to report continued engagement in HIV care than those with persistent viremia.
A new long-acting medicine that could make preventing HIV transition might soon be even for poor countries like Uganda thanks to agreements between producers and key HIV/AIDS prevention programme ...
A long-acting HIV jab promises near-perfect protection at just $40 a year, but 115 nations must wait for India's approval of ...
According to the World Health Organization (WHO), lenacapavir offers a highly effective, long-acting alternative to daily ...
For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating-and possibly even ...
Cuts proposed by the Trump administration and House Republicans could drive up new HIV cases by more than 200,000 by 2030, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback